| Authors: |
Sàbat P; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Ajenjo-Bauza M; Unit of Bioinformatics for Precision Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; Preclinical and experimental research in thoracic tumors (PRETT) group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain., Hierro C; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO)/CARE-IGTP (Germans Trias i Pujol Institute); Universitat Autònoma de Barcelona (UAB); Badalona, Barcelona, Spain., Ruffinelli JC; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Gil-Martin M; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Ochoa-de-Olza M; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO)/CARE-IGTP (Germans Trias i Pujol Institute); Universitat Autònoma de Barcelona (UAB); Badalona, Barcelona, Spain., Bergamino M; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO)/CARE-IGTP (Germans Trias i Pujol Institute); Universitat Autònoma de Barcelona (UAB); Badalona, Barcelona, Spain., Calvo M; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Soto-Castillo JJ; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Fina C; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Girona, Doctor Josep Trueta University Hospital; Girona, Spain. Precision Oncology Group (OncoGIR-Pro), Girona BiomedicaI Research Institute (IDIBGI-CERCA), Parc Hospitalari Martí i Julià, Salt, Girona, Spain., Llop S; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Stradella A; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Oliva M; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Notario L; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO)/CARE-IGTP (Germans Trias i Pujol Institute); Universitat Autònoma de Barcelona (UAB); Badalona, Barcelona, Spain., Carcereny E; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO)/CARE-IGTP (Germans Trias i Pujol Institute); Universitat Autònoma de Barcelona (UAB); Badalona, Barcelona, Spain., Teixidor-Vilà E; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Girona, Doctor Josep Trueta University Hospital; Girona, Spain. Precision Oncology Group (OncoGIR-Pro), Girona BiomedicaI Research Institute (IDIBGI-CERCA), Parc Hospitalari Martí i Julià, Salt, Girona, Spain., Domènech M; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Badalona-Applied Research Group in Oncology (B-ARGO)/CARE-IGTP (Germans Trias i Pujol Institute); Universitat Autònoma de Barcelona (UAB); Badalona, Barcelona, Spain., Jové M; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Villanueva R; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Alay A; Unit of Bioinformatics for Precision Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; Preclinical and experimental research in thoracic tumors (PRETT) group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain., Azuara D; Hereditary Cancer Program, Catalan Institute of Oncology (ICO)-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Molecular Mechanisms and Experimental Therapy in Oncology Program, Bellvitge Biomedical Research Institute (IDIBELL-ONCOBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., González-Acosta M; Hereditary Cancer Program, Catalan Institute of Oncology (ICO)-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Molecular Mechanisms and Experimental Therapy in Oncology Program, Bellvitge Biomedical Research Institute (IDIBELL-ONCOBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Otero-Torres S; Pharmacy Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Gausachs M; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain; Preclinical and experimental research in thoracic tumors (PRETT) group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain., Varela M; Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Laboratori Core d'Anàlisi Molecular, Hospital Universitari de Bellvitge-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Villatoro S; Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Laboratori Core d'Anàlisi Molecular, Hospital Universitari de Bellvitge-Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain., Solanes A; Hereditary Cancer Program, Catalan Institute of Oncology (ICO)-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain., Teulé A; Hereditary Cancer Program, Catalan Institute of Oncology (ICO)-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain., Cuadra C; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain., Moreno V; Unit of Bioinformatics for Precision Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; Preclinical and experimental research in thoracic tumors (PRETT) group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; Consorcio de Investigación Biomédica en Red de Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain; Department of Clinical Sciences, Faculty of Medicine and Health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), Universitat de Barcelona (UB). L'Hospitalet de Llobregat, Barcelona, Spain., Nadal E; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain; Preclinical and experimental research in thoracic tumors (PRETT) group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; Department of Clinical Sciences, Faculty of Medicine and Health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), Universitat de Barcelona (UB). L'Hospitalet de Llobregat, Barcelona, Spain., Cordero D; Unit of Bioinformatics for Precision Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; Preclinical and experimental research in thoracic tumors (PRETT) group, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; Consorcio de Investigación Biomédica en Red de Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain., Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology (ICO)-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Molecular Mechanisms and Experimental Therapy in Oncology Program, Bellvitge Biomedical Research Institute (IDIBELL-ONCOBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Martin-Liberal J; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Hospitalet; L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: jmartinliberal@iconcologia.net. |
